Tibet AIM Pharm. Inc. (SHE:002826)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2023	FY 2022	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Others	93.62M	141.53M	194.63M	97.10M	75.55M
Others Growth	-33.86%	-27.28%	100.45%	28.52%	-4.22%
Cardiovascular Medicines	84.21M	189.69M	336.27M	332.31M	253.44M
Cardiovascular Medicines Growth	-55.61%	-43.59%	1.19%	31.12%	-5.31%
Diabetes	474.06M	335.82M	325.84M	190.07M	149.42M
Diabetes Growth	41.17%	3.06%	71.43%	27.21%	59.54%
Gynecology	-	-	-	105.99M	124.21M
Gynecology Growth	-	-	-	-14.67%	9.86%
Total	651.88M	667.04M	856.73M	725.46M	602.62M
Total Growth	-2.27%	-22.14%	18.10%	20.38%	8.92%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2023	FY 2022	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
North China	124.42M	134.74M	183.28M	139.94M	88.32M
North China Growth	-7.66%	-26.48%	30.97%	58.45%	14.15%
East China	143.78M	158.90M	235.20M	202.51M	158.82M
East China Growth	-9.52%	-32.44%	16.15%	27.51%	8.65%
Northwest	52.89M	51.84M	65.84M	73.01M	53.18M
Northwest Growth	2.02%	-21.26%	-9.82%	37.30%	2.50%
Southwest	263.23M	224.00M	216.93M	158.05M	143.67M
Southwest Growth	17.52%	3.26%	37.26%	10.01%	21.40%
Northeast	67.56M	97.55M	155.47M	151.95M	158.64M
Northeast Growth	-30.75%	-37.25%	2.32%	-4.21%	-0.54%
Total	651.88M	667.04M	856.73M	725.46M	602.62M
Total Growth	-2.27%	-22.14%	18.10%	20.38%	8.92%

Source: S&P Global Market Intelligence.